Key Metrics
5.3
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.001 - 0.005
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.88
5-Year SI
5-year SI
- N/A 2-year SI
- 0.85 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q3
Oncology
SJR
- Q2 Oncology
- Q2 Hematology
- Q3 Cancer Research
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
1.04
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
4 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
25%
4 to 6 months
62%
7 to 9 months
10%
Above 9 months
3%
Did you find this useful?
Thank you for your feedback.
Topics Covered
- Lymphoma
- Drug discovery
- Rituximab
- Diffuse large B-cell lymphoma
- Lymphoblastic Leukemia
- Lenalidomide
- Central nervous system
- Hematopoietic stem cell transplantation
- Overall survival
- Polycythemia vera
- Immunotherapy
- Poor prognosis
- Bendamustine
- Minimal residual disease
- Follicular lymphoma
- B-cell lymphoma
- Systematic review
- Seroconversion
- Progression-free survival
- Bortezomib
Journal Specifications
| Overview | |
| Publisher | WILEY |
| Language | English |
| Frequency | Quarterly |
| General Details | |
| Language | English |
| Frequency | Quarterly |
| Publication Start Year | 1983 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Hematological Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect.
- 1 Nov 24
- Hematological oncology
-
Full paper
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia.
- 1 Nov 24
- Hematological oncology
-
Full paper
Title not available
- 1 Nov 24
- Hematological Oncology
-
Full paper
Characterizing second line and beyond therapies for primary central nervous system lymphomas.
- 1 Nov 24
- Hematological oncology
-
Full paper
Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35).
- 1 Nov 24
- Hematological oncology
-
Full paper
Allogeneic transplantation for adult T-cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy.
- 4 Oct 24
- Hematological oncology
Scite analysis
Powered by scite_
4.8k articles received 23.9k citations see all
- 1,146 Supporting
- 21,908 Mentioning
- 190 Contrasting
Editorial notices
- 3 Retractions
- 0 Withdrawals
- 1 Corrections
- 19 Errata
- 0 Expression of Concern
FAQs
How long has Hematological Oncology been actively publishing?
Hematological Oncology has been in operation since 1983 till date.
What is the publishing frequency of Hematological Oncology ?
Hematological Oncology published with a Quarterly frequency.
How many articles did Hematological Oncology publish last years ?
In 2023, Hematological Oncology published 841 articles.
What is the eISSN & pISSN for Hematological Oncology ?
For Hematological Oncology,eISSN is 1099-1069 and pISSN is0278-0232.
What is Citescore for Hematological Oncology ?
Citescore for Hematological Oncology is 5.3.
What is SNIP score for Hematological Oncology ?
SNIP score for Hematological Oncology is 1.04.
What is the SJR for Hematological Oncology ?
SJR for Hematological Oncology is Q3.
Who is the publisher of Hematological Oncology ?
WILEY is the publisher of Hematological Oncology.